for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Emergent Biosolutions Inc

EBS.N

Latest Trade

54.98USD

Change

2.40(+4.56%)

Volume

124,325

Today's Range

53.04

 - 

55.08

52 Week Range

39.11

 - 

69.70

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
52.58
Open
53.04
Volume
124,325
3M AVG Volume
7.88
Today's High
55.08
Today's Low
53.04
52 Week High
69.70
52 Week Low
39.11
Shares Out (MIL)
51.62
Market Cap (MIL)
2,838.27
Forward P/E
17.53
Dividend (Yield %)
--

Next Event

Q4 2019 Emergent BioSolutions Inc Earnings Release

Latest Developments

More

Emergent BioSolutions Reports Third Quarter Results

Emergent Biosolutions Receives EMA Prime Designation For Its Chikungunya Virus Vlp Vaccine Candidate

Emergent BioSolutions Awarded 10-Year HHS Contract to Deliver ACAM2000 Into the Strategic National Stockpile

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Emergent Biosolutions Inc

Emergent BioSolutions Inc. is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs). The PHTs operates through two categories: Chemical, Biological, Radiological and Nuclear, as well as explosive-related threats and emerging infectious diseases. It operates through four business units: Vaccines and Anti-infectives; Antibody Therapeutics; Devices, and Contract Manufacturing. Vaccines and Anti-infectives business unit consists of BioThrax, which is for the general use prophylaxis and post-exposure prophylaxis of anthrax disease. Devices business unit consists of marketed products, such as Reactive Skin Decontamination Lotion Kit (RSDL) and Trobigard (atropine sulfate, obidoxime chloride).

Industry

Biotechnology & Drugs

Contact Info

400 Professional Dr Ste 400

+1.240.6313200

https://emergentbiosolutions.com/

Executive Leadership

Fuad El-Hibri

Executive Chairman of the Board

Robert G. Kramer

President, Chief Executive Officer, Director

Richard S. Lindahl

Chief Financial Officer, Executive Vice President, Treasurer

Katherine Strei

Chief Human Resource Officer, Executive Vice President

Atul Saran

Executive Vice President, Corporate Development, General Counsel and Corporate Secretary

Key Stats

1.63 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.5K

2017

0.6K

2018

0.8K

2019(E)

1.1K
EPS (USD)

2016

1.570

2017

1.900

2018

2.330

2019(E)

2.999
Price To Earnings (TTM)
--
Price To Sales (TTM)
2.79
Price To Book (MRQ)
2.74
Price To Cash Flow (TTM)
26.33
Total Debt To Equity (MRQ)
79.56
LT Debt To Equity (MRQ)
78.58
Return on Investment (TTM)
-0.01
Return on Equity (TTM)
-0.00

Latest News

Latest News

BRIEF-Emergent Announces FDA Approval Of Change In Storage Conditions And Transfer Of Manufacturing For Its Cholera Vaccine

* EMERGENT BIOSOLUTIONS ANNOUNCES FDA APPROVAL OF CHANGE IN STORAGE CONDITIONS AND TRANSFER OF MANUFACTURING FOR ITS CHOLERA VACCINE

Emergent-Valneva Zika vaccine clears early trial

A vaccine to prevent infections caused by the deadly mosquito-borne Zika virus induced immune response and was found to be safe in an early stage trial, Emergent BioSolutions Inc and partner Valneva SE said on Monday.

Emergent BioSolutions to buy Narcan maker Adapt Pharma

Emergent BioSolutions Inc said on Tuesday it would buy privately held Adapt Pharma, beefing up its portfolio with Narcan, the only FDA approved needle-free emergency opioid overdose treatment.

Emergent BioSolutions to buy Adapt Pharma for up to $735 mln

Emergent BioSolutions Inc said on Tuesday it would buy privately held Adapt Pharma for up to $735 million to acquire its drug Narcan, the only needle-free emergency treatment approved to treat opioid overdose.

BRIEF-Emergent BioSolutions Reports Q1 Adjusted Loss Per Share $0.03

* EMERGENT BIOSOLUTIONS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Emergent BioSolutions ‍Appoints Richard Lindahl As New Executive Vice President And Chief Financial Officer​

* EMERGENT BIOSOLUTIONS ANNOUNCES EXECUTIVE MANAGEMENT CHANGES THAT ENHANCE EXECUTION OF COMPANY’S GROWTH STRATEGY

BRIEF-Emergent Biosolutions To Implement Stock Repurchase Program

* EMERGENT BIOSOLUTIONS TO IMPLEMENT STOCK REPURCHASE PROGRAM FOR UP TO $50 MILLION OF ITS COMMON STOCK

BRIEF-Emergent Biosolutions Awarded One-Year CDC Contract Valued At $26 Mln

* EMERGENT BIOSOLUTIONS AWARDED ONE-YEAR CDC CONTRACT VALUED AT $26 MILLION FOR VACCINIA IMMUNE GLOBULIN PROGRAM

BRIEF-Emergent Biosolutions And Valneva Initiate Clinical Study To Evaluate Vaccine Against Zika Virus

* EMERGENT BIOSOLUTIONS AND VALNEVA INITIATE PHASE 1 CLINICAL STUDY TO EVALUATE VACCINE CANDIDATE AGAINST ZIKA VIRUS

BRIEF-Valneva And Emergent Biosolutions Start Phase 1 Clinical Study To Evaluate Vaccine Candidate Against Zika Virus

* EMERGENT BIOSOLUTIONS AND VALNEVA INITIATE PHASE 1 CLINICAL STUDY TO EVALUATE VACCINE CANDIDATE AGAINST ZIKA VIRUS

BRIEF-Emergent BioSolutions Q4 Earnings Per Share $0.67

* EMERGENT BIOSOLUTIONS REPORTS FOURTH QUARTER AND TWELVE MONTHS 2017 FINANCIAL RESULTS

BRIEF-Emergent Biosolutions Sees FY 2017 Revenue $555 Million To $560 Million

* EMERGENT BIOSOLUTIONS ANNOUNCES PRELIMINARY 2017 FINANCIAL RESULTS AND PROVIDES 2018 FINANCIAL OUTLOOK

BRIEF-Emergent Biosolutions reports third quarter results

* Emergent Biosolutions reports third quarter and nine months 2017 financial results; raises calendar year 2017 guidance

BRIEF-Emergent Biosolutions awarded U.S. Department of State contract valued at up to $25 mln to supply nerve agent antidote auto-injector

* Emergent Biosolutions awarded U.S. Department of State contract valued at up to $25 million to supply nerve agent antidote auto-injector

BRIEF-Emergent Biosolutions completes acquisition of Raxibacumab from GSK​

* Emergent Biosolutions Inc - transaction anticipated to be additive by approximately $9 million to revenue and neutral to GAAP net income for full year 2017

BRIEF-Emergent BioSolutions signs five-year follow-on contract with DoD valued at up to $171 mln​

* Emergent BioSolutions to supply DoD with chemical threat countermeasure RSDL under five-year follow-on contract valued at up to $171 million

BRIEF-Emergent BioSolutions awarded $63 mln BARDA contract to develop treatment for cyanide exposure

* Emergent BioSolutions - awarded contract valued at about $63 mln by Biomedical Advanced Research And Development Authority

BRIEF-Emergent Biosolutions Q2 earnings per share $0.11

* Emergent Biosolutions reports second quarter and six months 2017 financial results; reaffirms calendar year 2017 guidance

BRIEF-Emergent Biosolutions awarded $23 mln to develop novel multi-drug auto-injector for U.S. Department Of Defense

* Emergent Biosolutions awarded $23 million to develop novel multi-drug auto-injector for U.S. Department of defense Source text for Eikon: Further company coverage:

BRIEF-Emergent Biosolutions Inc - ‍announced a licensing agreement with Valneva SE for global exclusive rights to Valneva's zika vaccine technology, ZIKV​

* Emergent Biosolutions Inc - announced a licensing agreement with Valneva SE for global exclusive rights to Valneva's zika vaccine technology, ZIKV

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up